US20060018938A1 - Foam skin cream, use of the foam skin protection cream and a process of its preparation - Google Patents
Foam skin cream, use of the foam skin protection cream and a process of its preparation Download PDFInfo
- Publication number
- US20060018938A1 US20060018938A1 US11/180,913 US18091305A US2006018938A1 US 20060018938 A1 US20060018938 A1 US 20060018938A1 US 18091305 A US18091305 A US 18091305A US 2006018938 A1 US2006018938 A1 US 2006018938A1
- Authority
- US
- United States
- Prior art keywords
- temperature
- phase
- skin
- weight
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000006260 foam Substances 0.000 title claims abstract description 54
- 239000002884 skin cream Substances 0.000 title claims abstract description 36
- 239000006071 cream Substances 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 7
- 230000008569 process Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 19
- 239000000194 fatty acid Substances 0.000 claims abstract description 19
- 229930195729 fatty acid Natural products 0.000 claims abstract description 19
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 14
- 239000004909 Moisturizer Substances 0.000 claims abstract description 11
- -1 alkyl sarcosinates Chemical compound 0.000 claims abstract description 11
- 239000007957 coemulsifier Substances 0.000 claims abstract description 11
- 230000001333 moisturizer Effects 0.000 claims abstract description 11
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 8
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 8
- 229960000458 allantoin Drugs 0.000 claims abstract description 8
- 239000010452 phosphate Substances 0.000 claims abstract description 8
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 8
- 239000003380 propellant Substances 0.000 claims abstract description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 7
- 238000002844 melting Methods 0.000 claims abstract description 6
- 230000008018 melting Effects 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 6
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 239000000443 aerosol Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 239000001273 butane Substances 0.000 claims description 4
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical group CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001294 propane Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 2
- 229940071089 sarcosinate Drugs 0.000 claims description 2
- 239000008240 homogeneous mixture Substances 0.000 claims 8
- 230000000996 additive effect Effects 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000011493 spray foam Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 abstract description 10
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 239000000126 substance Substances 0.000 description 34
- 201000004624 Dermatitis Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000004243 sweat Anatomy 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 5
- 150000002191 fatty alcohols Chemical class 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000011814 protection agent Substances 0.000 description 2
- 238000009991 scouring Methods 0.000 description 2
- 230000037372 slightly dry skin Effects 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- KGULFLCOPRYBEV-KTKRTIGZSA-N 2-[2-[2-[(z)-octadec-9-enoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCO KGULFLCOPRYBEV-KTKRTIGZSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- DHVLDKHFGIVEIP-UHFFFAOYSA-N 2-bromo-2-(bromomethyl)pentanedinitrile Chemical compound BrCC(Br)(C#N)CCC#N DHVLDKHFGIVEIP-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010046740 Urticaria cholinergic Diseases 0.000 description 1
- 206010046742 Urticaria contact Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 201000005681 cholinergic urticaria Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000013046 dyshidrosis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 229940075643 oleth-3 Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 201000011414 pompholyx Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000008207 working material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/556—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
Definitions
- the present invention relates to a foam skin cream, uses of the foam skin protection cream and a process for its preparation.
- the galenic principle of an emulsoid two-phase system having lipophilic or hydrophobic components and, on the other hand, hydrophilic components has been known for the production of foam preparations for skin care.
- the application of these foam preparations to the treated skin forms a two-dimensional two-phase network, the hydrophilic components bind to the keratin of the horny layer and enable the evaporation of sweat while the lipophilic components inhibit the permeation of moisture (including the penetrated sweat) on the skin surface.
- the foam in contrast to other creams building a barrier, is absorbed in less than a minute, does not leave any grease traces on the working materials and prevents heat built-up or even maceration effects from the action of sweat, the foam has enjoyed rapidly growing popularity as a protective agent against occupational action of moisture. Further details about the per se known foam skin creams can be seen, in particular, from “Haut”, issue 4, 1992, by R. Rudolph, L. Bade, B. Brüggemann.
- lipid-containing skin protection foams which are indicated for dry sensitive skin and chronical-rhagadiform eczemas. Ingredients are also disclosed therein.
- the skin protection foams described therein are protective against a lot of occupational noxious matters, such as acid permanent waving liquids in the hairdresser's trade, lyes, oils, disinfectants, cleaning and rinsing agents, but also against water, moisture, sweat, feces, urine and mineral dusts.
- EP 0 598 412 also relates to skin protection foams; PTFE is described as an active principle.
- DE-C-33 30 628 relates to skin protection and care-lotions containing silicone oils, partially neutralized stearic acid, fatty alcohols and their ethoxylated derivatives, ethoxylated wool alcohols, cetyl/stearyl alcohol, vaseline, thickeners and water.
- the lotions disclosed therein are said to be quickly absorbed without leaving an annoying grease film on the skin for extended periods of time.
- emulsifiers which can be employed in skin care agents are found in DE-A-195 42 572. This reference suggests emulsifiers which contain from 43 to 90% by weight of alkyl and/or alkenyl oligoglycosides and from 10 to 57% by weight of fatty alcohols. These emulsifiers are particularly suitable for the preparation of highly viscous, sensorily light oil-in-water emulsions having a long shelf life.
- the German utility model DE-U-9308050 relates to a skin protection foam used against skin-aggressive agents.
- This foam consists of an aqueous emulsion containing fatty acid esters with good skin compatibility for the production of a moisture-permeable film, polyhydric alcohol for stably dispersing the active agents and controlling the humidity of the film, emulsifiers for improving foam stability, surfactants for reducing the surface tension and optionally neutralizing agents for resins and emulsifiers.
- Gaseous hydrocarbons may be used as propellants, for example, propane, butane or isobutane and mixtures thereof. However, the foams described do not contain any free fatty acids.
- Aerosoles are complicated physical-chemical structures which do not form under arbitrary circumstances.
- a special balance between the foam-forming components is important. Slight shifts in the composition may already result in a collapse of the foam; thus, a formulation of per se active substances may not be capable of being formulated as a foam without further provisions.
- the object of the invention is surprisingly achieved by a base formulation of a foam skin cream having the features of claim 1 .
- Dependent claims 2 to 12 relate to preferred embodiments of the foam skin cream according to the invention.
- Claims 13 to 16 relate to uses of the foam skin cream according to the invention, whereas claim 17 relates to a process for preparing the base of a foam skin cream according to the invention.
- the foam skin cream according to the invention can be obtained by:
- the product obtainable according to this process can be directly employed as a foam skin cream in the industrial field for the protection from or reduction of the absorption of cancerogenic substances, such as polycyclic aromatic hydrocarbons.
- This mixture is capable of providing effective protection for persons whose skin has already been exposed to cancerogenic substances, such as polycyclic aromatic hydrocarbons.
- the mixture is suitable for providing protection to persons from the action of acids, lyes (not above pH 11), scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
- the foam skin cream according to the invention contains fatty acids, especially C 12 -C 22 fatty acids, and may optionally additionally contain unsaturated and/or polyunsaturated fatty acids.
- Useful fatty acids which are saturated include, in particular, the naturally occurring C 12 -C 22 fatty acids, especially stearic acid and palmitic acid. Myristic acid may also be used.
- Useful unsaturated fatty acids include, in particular, those having up to three unsaturated bonds in their hydrocarbon chain. Unsaturated fatty acids are found, for example, in fractions of coconut fat.
- Useful coemulsifiers include per se known coemulsifiers, especially triceteareth-4-phosphate, sodium laureth-4-phosphate or oleth-3 and other lipophilic emulsifiers based on fatty alcohols with a low degree of ethoxylation.
- Phase I may additionally contain paraffinum liquidum.
- Emulsifiers to be used in phase I may include those based on fatty alcohols and those based on partial esters of fatty acids. Particularly preferred fatty alcohols include cetearyl alcohol. Glyceryl stearate, for example, may be employed as a partial ester of a fatty acid.
- the moisturizers to be used in phase II include, in particular, propylene glycol and/or polyhydric alcohols, such as glycerol.
- emulsifiers to be used in phase II there may be mentioned alkyl sarcosinates, such as lauroyl, lauryl, cetyl sarcosinates.
- the mixture obtainable according to claim 1 also serves as a base for other foam skin creams which may be employed in a wide range of applications for protecting the skin and alleviating dermatological dysfunctions.
- one or more preservatives may be added to the foam skin cream according to the invention.
- substances such as methyldibromoglutaronitrile and/or phenoxyethanol have proven to be suitable preservatives. These substances may be added in amounts of from 0.01 to 1% by weight.
- the emulsifiers, fatty acids, coemulsifiers, moisturizers and skin care agents, especially allantoin, panthenol etc. are used in the following amounts:
- a preferable foam skin cream according to the invention contains:
- the foam skin cream according to the invention additionally contains a silicone-containing substance, such as dimethicone.
- This substance is added to phase I.
- it is present in amounts of from 0.05 to 1% by weight.
- the foam skin cream according to the invention may additionally contain one or more refatting substances in phase I, such as decyl oleate, isohexadecane, stearic acid glycol ester, coconut fatty acid ethanolamide, corn oil, peanut oil, almond oil, sesame oil, olive oil, jojoba oil, soybean oil, wool wax alcohols, paraffin, medium-chain triglycerides, oleic acid oleyl esters, white petrolatum, macrogol-glycerol hydroxystearate, hydrogenated castor oil, castor oil from Ricinus communis, avocado oil, wheat germ oil, palmitic acid isopropyl ester, cetyl palmitate, myristic acid myristyl ester and/or octyldodecanol.
- refatting substances in phase I such as decyl oleate, isohexadecane, stearic acid glycol ester, coconut fatty acid ethanolamide, corn oil, peanut
- the foam skin cream contains amounts of from 0.5 to 2% by weight of decyl oleate and/or from 0.5 to 2% by weight of octyldecanol, or another of the refatting substances mentioned, if the product is to be used for normal skin.
- the total amount of refatting substances is to be such that the skin protection foam is not destroyed.
- An amount of about 4% by weight of refatting substances is sufficient for normal to slightly dry skin. If dry skin is to be treated with the foam skin cream according to the invention, amounts of from 3 to 6% by weight of a component of the refatting substances, such as, in particular, decyl oleate and/or octyldecanol, are recommendable.
- the total amount of refatting components is to be about 12% at most for slightly dry skin. If even more severely dry skin is treated, the amount of refatting substances is from about 6 to 9% by weight if a component such as decyl oleate is used, and from 6 to 9% by weight if octyldecanol is used. The amount of refatting substance may then be up to 20% by weight.
- foam skin creams are suitable for the care and protection of the skin, especially from aggressive substances, such as scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
- aggressive substances such as scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
- the foam skin creams are also suitable for the treatment or alleviation of dermatological diseases.
- dermatological diseases such as allergic contact dermatitis type I and IV, cumulative-subtoxic eczema, toxic-irritative eczema, microbial-dysregulative eczema, atopic dermatitis, atopic palmoplantar eczema, dyshidrosis, hyperhidrosis, contact urticaria, intertriginous eczema in connection with hemorrhoids, various weeping fungal infections, e.g., interdigital mycosis, perleches, psoriasis vulgaris, ulcus cruris, cholinergic urticaria, diaper dermatitis.
- dermatological diseases such as allergic contact dermatitis type I and IV, cumulative-subtoxic eczema, toxic-irritative eczema, microbial-dysregulative eczema,
- Such hydratizing substances include, in particular, urea, ethoxydiglycol, sodium chloride, magnesium chloride, sorbitol, dexpanthenol, sodium lactate, allantoin, hyaluronic acid, vitamin E, linolenic acid.
- the amount of those substances can be from 1 to 20% by weight or more of the respective substances, depending on the severity of the disease to be treated. These quantities also apply, in particular, to urea which may also be present in amounts of from 3 to 15% by weight or from 12.5 to 15% by weight.
- the foam skin cream according to the invention may also be used for psoriasis.
- skin care substances such as polyunsaturated fatty acids (PUFA) may be added to the foam skin cream according to the invention.
- PUFA polyunsaturated fatty acids
- omega-6 fatty acids as known, for example, from evening primrose oil and borage oil. Both synthetic omega-6 fatty acids and those obtained from the mentioned plant extracts may be employed.
- soothing substances such as chamomile extract, as another fraction which may be admixed with the foam skin cream according to the invention.
- Skin-active vitamins such as vitamins A, E and F
- admixing the following substances has proven useful: from 3 to 7% by weight of Calendula extract, from 3 to 7% by weight of Hamamelis extract, from 3 to 7% by weight of chamomile extract, from 3 to 7% by weight of tea tree oil extract, from 1 to 5% by weight of decyl oleate, from 1 to 5% by weight of octyldodecanol.
- the process according to the invention for the preparation of the foam skin protection cream according to the invention comprises the following steps:
- the skin protection cream according to the invention is prepared in a heatable and coolable closed apparatus with a self-withdrawing homogenisator and a heatable metering funnel (preferably in a Koruma multipurpose apparatus).
- phase I is effected in a heatable metering funnel by melting at 75° C. a mixture containing 2% by weight of glyceryl stearate, 4% by weight of cetearyl alcohol, 5% by weight of stearic acid, 1% by weight of paraffin and 1% by weight of triceteareth-4-phosphate, followed by metering this phase with stirring to phase II previously prepared in the heatable and coolable closed apparatus with a self-withdrawing homogenisator.
- Phase II consists of an aqueous mixture containing 2.5% by weight of propylene glycol, 2.5% by weight of glycerol, 2% by weight of sodium lauroylsarcosinate and 0.3% by weight of allantoin. The amount of water is 79.7% by weight. Homogeneous mixing of phases I and II is to be provided.
- phase I The metering of phase I is performed at a temperature of 75° C. Both phases are combined with constant stirring at a medium stirring speed, and care must be taken that homogenization is effected uniformly.
- the temperature is maintained at 75° C. for between 5 and 20 min.
- the mixture obtained is cooled to a temperature of between 30 and 40° C. with constant stirring.
- the further substances may be added. This may include adjusting the pH value to between 7.8 and 8.0.
- 2-amino-2-methyl-1-propanol is used. Stirring is continued for a sufficient period of time until the pH value has stabilized, followed by filling into suitable storage tanks or into the corresponding spraying containers. In the latter case, 91% of drug is filled together with 9% of butane/propane.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Dairy Products (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
- preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, emulsifiers, coemulsifiers, such as triceteareth-4-phosphate, followed by metering it with stirring to a phase II temperature-controlled at 75° C. obtained from an aqueous mixture containing moisturizers, such as propylene glycol and/or polyhydric alcohols, especially glycerol, emulsifiers, such as alkyl sarcosinates, and skin care additives, such as allantoin; wherein homogeneous mixing of phases I and II is provided and said metering is performed at a temperature of 75° C.; after the metered addition, the temperature is maintained at 75° C. for a period of between 5 and 20 minutes; whereupon the temperature of the thus obtained mixture is lowered to a temperature of between 30 and 40° C. with constant stirring; the pH value is adjusted to from 7.6 to 8.2, preferably with a skin-compatible basic organic compound, and the mixture obtained is filled into dosage forms with the addition of a propellant.
Description
- The present invention relates to a foam skin cream, uses of the foam skin protection cream and a process for its preparation.
- The galenic principle of an emulsoid two-phase system having lipophilic or hydrophobic components and, on the other hand, hydrophilic components has been known for the production of foam preparations for skin care. The application of these foam preparations to the treated skin forms a two-dimensional two-phase network, the hydrophilic components bind to the keratin of the horny layer and enable the evaporation of sweat while the lipophilic components inhibit the permeation of moisture (including the penetrated sweat) on the skin surface. As the foam, in contrast to other creams building a barrier, is absorbed in less than a minute, does not leave any grease traces on the working materials and prevents heat built-up or even maceration effects from the action of sweat, the foam has enjoyed rapidly growing popularity as a protective agent against occupational action of moisture. Further details about the per se known foam skin creams can be seen, in particular, from “Haut”, issue 4, 1992, by R. Rudolph, L. Bade, B. Brüggemann.
- In “hautnah derm” 10 (1994), 344-351, B. Kunze reports lipid-containing skin protection foams which are indicated for dry sensitive skin and chronical-rhagadiform eczemas. Ingredients are also disclosed therein. The skin protection foams described therein are protective against a lot of occupational noxious matters, such as acid permanent waving liquids in the hairdresser's trade, lyes, oils, disinfectants, cleaning and rinsing agents, but also against water, moisture, sweat, feces, urine and mineral dusts.
- EP 0 598 412 also relates to skin protection foams; PTFE is described as an active principle.
- DE-C-33 30 628 relates to skin protection and care-lotions containing silicone oils, partially neutralized stearic acid, fatty alcohols and their ethoxylated derivatives, ethoxylated wool alcohols, cetyl/stearyl alcohol, vaseline, thickeners and water. The lotions disclosed therein are said to be quickly absorbed without leaving an annoying grease film on the skin for extended periods of time.
- Information about emulsifiers which can be employed in skin care agents are found in DE-A-195 42 572. This reference suggests emulsifiers which contain from 43 to 90% by weight of alkyl and/or alkenyl oligoglycosides and from 10 to 57% by weight of fatty alcohols. These emulsifiers are particularly suitable for the preparation of highly viscous, sensorily light oil-in-water emulsions having a long shelf life. The German utility model DE-U-9308050 relates to a skin protection foam used against skin-aggressive agents. This foam consists of an aqueous emulsion containing fatty acid esters with good skin compatibility for the production of a moisture-permeable film, polyhydric alcohol for stably dispersing the active agents and controlling the humidity of the film, emulsifiers for improving foam stability, surfactants for reducing the surface tension and optionally neutralizing agents for resins and emulsifiers. Gaseous hydrocarbons may be used as propellants, for example, propane, butane or isobutane and mixtures thereof. However, the foams described do not contain any free fatty acids.
- Aerosoles are complicated physical-chemical structures which do not form under arbitrary circumstances. In Particular, a special balance between the foam-forming components is important. Slight shifts in the composition may already result in a collapse of the foam; thus, a formulation of per se active substances may not be capable of being formulated as a foam without further provisions.
- Especially in occupational applications, skin creams are often found unpleasant because the “fatting” components remain too long on the skin and lead to annoying finger traces or generally to an unpleasant feeling. This has been remedied to some extent by the per se known skin foams since they help preventing or reducing overload of the skin with the fatting matters. Nevertheless, it is desirable to find even more acceptance by the user, especially in the long-term use of skin protection agents.
- It has been the object of the present invention to extend the application range of skin protection foams by providing a formulation which is highly accepted by the user, the admixture of a wide variety of other substances being allowed without destroying the aerosol employed or deteriorating the properties of the aerosol.
- The object of the invention is surprisingly achieved by a base formulation of a foam skin cream having the features of claim 1. Dependent claims 2 to 12 relate to preferred embodiments of the foam skin cream according to the invention. Claims 13 to 16 relate to uses of the foam skin cream according to the invention, whereas claim 17 relates to a process for preparing the base of a foam skin cream according to the invention.
- The foam skin cream according to the invention can be obtained by
- preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, emulsifiers, coemulsifiers, such as triceteareth-4-phosphate, followed by metering it with stirring to
- a phase II temperature-controlled at 75° C. obtained from an aqueous mixture containing moisturizers, such as propylene glycol and/or polyhydric alcohols, especially glycerol, emulsifiers, such as alkyl sarcosinates, and skin care additives, such as allantoin;
- wherein homogeneous mixing of phases I and II is provided and said metering is performed at a temperature of 75° C.;
- after the metered addition, the temperature is maintained at 75° C. for a period of between 5 and 20 minutes; whereupon the temperature of the thus obtained mixture is lowered to a temperature of between 30 and 40° C. with constant stirring;
- the pH value is adjusted to from 7.6 to 8.2, preferably with a skin-compatible basic organic compound, and the mixture obtained is filled into dosage forms with the addition of a propellant.
- At the one hand, the product obtainable according to this process can be directly employed as a foam skin cream in the industrial field for the protection from or reduction of the absorption of cancerogenic substances, such as polycyclic aromatic hydrocarbons. This mixture is capable of providing effective protection for persons whose skin has already been exposed to cancerogenic substances, such as polycyclic aromatic hydrocarbons. In addition, the mixture is suitable for providing protection to persons from the action of acids, lyes (not above pH 11), scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
- The foam skin cream according to the invention contains fatty acids, especially C12-C22 fatty acids, and may optionally additionally contain unsaturated and/or polyunsaturated fatty acids. Useful fatty acids which are saturated include, in particular, the naturally occurring C12-C22 fatty acids, especially stearic acid and palmitic acid. Myristic acid may also be used. Useful unsaturated fatty acids include, in particular, those having up to three unsaturated bonds in their hydrocarbon chain. Unsaturated fatty acids are found, for example, in fractions of coconut fat. Useful coemulsifiers include per se known coemulsifiers, especially triceteareth-4-phosphate, sodium laureth-4-phosphate or oleth-3 and other lipophilic emulsifiers based on fatty alcohols with a low degree of ethoxylation.
- Phase I may additionally contain paraffinum liquidum. Emulsifiers to be used in phase I may include those based on fatty alcohols and those based on partial esters of fatty acids. Particularly preferred fatty alcohols include cetearyl alcohol. Glyceryl stearate, for example, may be employed as a partial ester of a fatty acid.
- The moisturizers to be used in phase II include, in particular, propylene glycol and/or polyhydric alcohols, such as glycerol. As particular emulsifiers to be used in phase II, there may be mentioned alkyl sarcosinates, such as lauroyl, lauryl, cetyl sarcosinates.
- The mixture obtainable according to claim 1 also serves as a base for other foam skin creams which may be employed in a wide range of applications for protecting the skin and alleviating dermatological dysfunctions.
- If desired, one or more preservatives may be added to the foam skin cream according to the invention. In particular, substances such as methyldibromoglutaronitrile and/or phenoxyethanol have proven to be suitable preservatives. These substances may be added in amounts of from 0.01 to 1% by weight.
- Preferably, the emulsifiers, fatty acids, coemulsifiers, moisturizers and skin care agents, especially allantoin, panthenol etc., are used in the following amounts:
- from 4 to 15% by weight of oil-in-water emulsifier;
- from 1 to 10% by weight of fatty acid, especially from 4 to 7% by weight, preferably from 4.5 to 6% by weight;
- from 0.4 to 2.3% by weight of coemulsifier;
- from 1 to 10% by weight of moisturizer;
- from 0.05 to 1% by weight of skin care agent; and
- water as the balance to make 100% by weight.
- A preferable foam skin cream according to the invention contains:
- from 1 to 3% by weight of glyceryl stearate;
- from 3 to 6% by weight of cetearyl alcohol;
- from 4 to 6% by weight of stearic acid;
- from 0.5 to 2% by weight of paraffin;
- from 0.4 to 2.3% by weight of triceteareth-4-phosphate;
- from 1.5 to 4% by weight of propylene glycol;
- from 1.3 to 4.2% by weight of glycerol;
- from 1 to 3% by weight of cetyl sarcosinate;
- from 0.05 to 1% by weight of allantoin; and
- water as the balance to make 100% by weight.
- In another preferred embodiment, the foam skin cream according to the invention additionally contains a silicone-containing substance, such as dimethicone. This substance is added to phase I. Preferably, it is present in amounts of from 0.05 to 1% by weight.
- In addition, the foam skin cream according to the invention may additionally contain one or more refatting substances in phase I, such as decyl oleate, isohexadecane, stearic acid glycol ester, coconut fatty acid ethanolamide, corn oil, peanut oil, almond oil, sesame oil, olive oil, jojoba oil, soybean oil, wool wax alcohols, paraffin, medium-chain triglycerides, oleic acid oleyl esters, white petrolatum, macrogol-glycerol hydroxystearate, hydrogenated castor oil, castor oil from Ricinus communis, avocado oil, wheat germ oil, palmitic acid isopropyl ester, cetyl palmitate, myristic acid myristyl ester and/or octyldodecanol.
- In particular, the foam skin cream contains amounts of from 0.5 to 2% by weight of decyl oleate and/or from 0.5 to 2% by weight of octyldecanol, or another of the refatting substances mentioned, if the product is to be used for normal skin. The total amount of refatting substances is to be such that the skin protection foam is not destroyed. An amount of about 4% by weight of refatting substances is sufficient for normal to slightly dry skin. If dry skin is to be treated with the foam skin cream according to the invention, amounts of from 3 to 6% by weight of a component of the refatting substances, such as, in particular, decyl oleate and/or octyldecanol, are recommendable. If more than one component is used, the total amount of refatting components is to be about 12% at most for slightly dry skin. If even more severely dry skin is treated, the amount of refatting substances is from about 6 to 9% by weight if a component such as decyl oleate is used, and from 6 to 9% by weight if octyldecanol is used. The amount of refatting substance may then be up to 20% by weight.
- Like the products without silicone-containing substances, the latter foam skin creams are suitable for the care and protection of the skin, especially from aggressive substances, such as scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
- The foam skin creams are also suitable for the treatment or alleviation of dermatological diseases. This includes, in particular, dermatological diseases such as allergic contact dermatitis type I and IV, cumulative-subtoxic eczema, toxic-irritative eczema, microbial-dysregulative eczema, atopic dermatitis, atopic palmoplantar eczema, dyshidrosis, hyperhidrosis, contact urticaria, intertriginous eczema in connection with hemorrhoids, various weeping fungal infections, e.g., interdigital mycosis, perleches, psoriasis vulgaris, ulcus cruris, cholinergic urticaria, diaper dermatitis.
- It may be indicated to include substances which can increase the moisture content of the skin, in addition to refatting substances. Such hydratizing substances include, in particular, urea, ethoxydiglycol, sodium chloride, magnesium chloride, sorbitol, dexpanthenol, sodium lactate, allantoin, hyaluronic acid, vitamin E, linolenic acid. The amount of those substances can be from 1 to 20% by weight or more of the respective substances, depending on the severity of the disease to be treated. These quantities also apply, in particular, to urea which may also be present in amounts of from 3 to 15% by weight or from 12.5 to 15% by weight. The foam skin cream according to the invention may also be used for psoriasis.
- One particularly important field of application concerns the prophylaxis and treatment of diabetic foot. Due to accompanying symptoms of diabetes, diabetics suffer from dry skin which in the course of the diseases favors damage to the extremities, up to an extent where amputation becomes necessary in the case of those having been diabetic for many years. Prophylactic application of skin protection agents which provide an improvement of the skin parameters in diabetics can prevent the development of diabetic foot.
- In addition, skin care substances, such as polyunsaturated fatty acids (PUFA), may be added to the foam skin cream according to the invention. These include, in particular, omega-6 fatty acids as known, for example, from evening primrose oil and borage oil. Both synthetic omega-6 fatty acids and those obtained from the mentioned plant extracts may be employed.
- Further, there may be used soothing substances, such as chamomile extract, as another fraction which may be admixed with the foam skin cream according to the invention.
- Skin-active vitamins, such as vitamins A, E and F, may be admixed with the foam skin cream according to the invention in effective amounts. Especially for the treatment and prevention of diaper dermatitis, admixing the following substances has proven useful: from 3 to 7% by weight of Calendula extract, from 3 to 7% by weight of Hamamelis extract, from 3 to 7% by weight of chamomile extract, from 3 to 7% by weight of tea tree oil extract, from 1 to 5% by weight of decyl oleate, from 1 to 5% by weight of octyldodecanol.
- The process according to the invention for the preparation of the foam skin protection cream according to the invention comprises the following steps:
- preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, coemulsifiers, such as triceteareth-4-phosphate, followed by metering this phase with stirring to
- a phase II molten at 75° C. obtained from an aqueous mixture containing moisturizers, such as propylene glycol and/or polyhydric alcohols, especially glycerol, emulsifiers, such as alkyl sarcosinates, and skin care additives, such as allantoin;
- wherein homogeneous mixing of phases I and II is provided and said metering is performed at a temperature of 75° C.;
- after the addition of phase I to phase II, the temperature is maintained at 75° C. for a period of between 5 and 20 minutes; whereupon the temperature of the thus obtained mixture is lowered to a temperature of between 30 and 40° C. with constant stirring;
- adjusting the pH value to from 7.6 to 8.2, preferably with a skin-compatible basic organic compound, and filling into containers with the addition of a propellant.
- The invention will be further illustrated by the following Example.
- The skin protection cream according to the invention is prepared in a heatable and coolable closed apparatus with a self-withdrawing homogenisator and a heatable metering funnel (preferably in a Koruma multipurpose apparatus).
- The preparation of phase I is effected in a heatable metering funnel by melting at 75° C. a mixture containing 2% by weight of glyceryl stearate, 4% by weight of cetearyl alcohol, 5% by weight of stearic acid, 1% by weight of paraffin and 1% by weight of triceteareth-4-phosphate, followed by metering this phase with stirring to phase II previously prepared in the heatable and coolable closed apparatus with a self-withdrawing homogenisator. Phase II consists of an aqueous mixture containing 2.5% by weight of propylene glycol, 2.5% by weight of glycerol, 2% by weight of sodium lauroylsarcosinate and 0.3% by weight of allantoin. The amount of water is 79.7% by weight. Homogeneous mixing of phases I and II is to be provided.
- The metering of phase I is performed at a temperature of 75° C. Both phases are combined with constant stirring at a medium stirring speed, and care must be taken that homogenization is effected uniformly. The temperature is maintained at 75° C. for between 5 and 20 min. The mixture obtained is cooled to a temperature of between 30 and 40° C. with constant stirring.
- Then, after a temperature of 40° C. has been reached, the further substances may be added. This may include adjusting the pH value to between 7.8 and 8.0. For this purpose, 2-amino-2-methyl-1-propanol is used. Stirring is continued for a sufficient period of time until the pH value has stabilized, followed by filling into suitable storage tanks or into the corresponding spraying containers. In the latter case, 91% of drug is filled together with 9% of butane/propane.
Claims (12)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/180,913 US20060018938A1 (en) | 1997-08-18 | 2005-07-14 | Foam skin cream, use of the foam skin protection cream and a process of its preparation |
US12/000,314 US20080213193A1 (en) | 1997-08-18 | 2007-12-11 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19735591.9 | 1997-08-18 | ||
DE19735591 | 1997-08-18 | ||
US09/485,930 US6423323B2 (en) | 1997-08-18 | 1998-08-18 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
PCT/EP1998/005232 WO1999008649A2 (en) | 1997-08-18 | 1998-08-18 | Foaming skin cream |
US10/196,726 US20030059394A1 (en) | 1997-08-18 | 2002-07-17 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US11/180,913 US20060018938A1 (en) | 1997-08-18 | 2005-07-14 | Foam skin cream, use of the foam skin protection cream and a process of its preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/196,726 Continuation US20030059394A1 (en) | 1997-08-18 | 2002-07-17 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/000,314 Continuation US20080213193A1 (en) | 1997-08-18 | 2007-12-11 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060018938A1 true US20060018938A1 (en) | 2006-01-26 |
Family
ID=7839199
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/485,930 Expired - Lifetime US6423323B2 (en) | 1997-08-18 | 1998-08-18 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US10/196,726 Abandoned US20030059394A1 (en) | 1997-08-18 | 2002-07-17 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US11/180,913 Abandoned US20060018938A1 (en) | 1997-08-18 | 2005-07-14 | Foam skin cream, use of the foam skin protection cream and a process of its preparation |
US12/000,314 Abandoned US20080213193A1 (en) | 1997-08-18 | 2007-12-11 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/485,930 Expired - Lifetime US6423323B2 (en) | 1997-08-18 | 1998-08-18 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
US10/196,726 Abandoned US20030059394A1 (en) | 1997-08-18 | 2002-07-17 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/000,314 Abandoned US20080213193A1 (en) | 1997-08-18 | 2007-12-11 | Foam skin cream, uses of the foam skin protection cream and a process for its preparation |
Country Status (11)
Country | Link |
---|---|
US (4) | US6423323B2 (en) |
EP (1) | EP1014916B2 (en) |
JP (1) | JP4057234B2 (en) |
AT (1) | ATE210954T1 (en) |
AU (1) | AU9162498A (en) |
CA (1) | CA2300054C (en) |
DE (1) | DE59802564D1 (en) |
DK (1) | DK1014916T4 (en) |
ES (1) | ES2170522T5 (en) |
PT (1) | PT1014916E (en) |
WO (1) | WO1999008649A2 (en) |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265240A1 (en) * | 2003-04-28 | 2004-12-30 | Foamix Ltd. | Foamable iodine composition |
US20050031547A1 (en) * | 2003-08-04 | 2005-02-10 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050069566A1 (en) * | 2003-08-04 | 2005-03-31 | Foamix Ltd. | Foam carrier containing amphiphilic copolymeric gelling agent |
US20050075407A1 (en) * | 2003-08-25 | 2005-04-07 | Foamix Ltd. | Foam incorporating eutetic mixture |
US20050074414A1 (en) * | 2002-10-25 | 2005-04-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US20050186147A1 (en) * | 2004-02-04 | 2005-08-25 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
US20050205086A1 (en) * | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
US20050232869A1 (en) * | 2002-10-25 | 2005-10-20 | Foamix Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20050244342A1 (en) * | 2002-10-25 | 2005-11-03 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US20050271598A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Body cavity foams |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US20060269485A1 (en) * | 2002-11-29 | 2006-11-30 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
US20060275221A1 (en) * | 2005-05-09 | 2006-12-07 | Foamix Ltd. | Saccharide foamable compositions |
US20070020213A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20070020304A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20070098647A1 (en) * | 2005-09-28 | 2007-05-03 | Neubourg Skin Care Gmbh & Co. Kg | Skin care products |
US20070253911A1 (en) * | 2002-10-25 | 2007-11-01 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20070292359A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20080044444A1 (en) * | 2002-10-25 | 2008-02-21 | Foamix Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US20080152596A1 (en) * | 2005-07-19 | 2008-06-26 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US20080166303A1 (en) * | 2006-09-08 | 2008-07-10 | Dov Tamarkin | Colored or colorable foamable composition and foam |
US20080206155A1 (en) * | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US20080253973A1 (en) * | 2002-10-25 | 2008-10-16 | Foamix Ltd. | Sensation modifying topical composition foam |
US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080267890A1 (en) * | 2005-01-20 | 2008-10-30 | Kayban Pty Ltd. | Anti-Microbial Agent |
US20080292560A1 (en) * | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
US20080299220A1 (en) * | 2003-08-04 | 2008-12-04 | Dov Tamarkin | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20080317679A1 (en) * | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US20090130029A1 (en) * | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20100310476A1 (en) * | 2007-12-07 | 2010-12-09 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US20160107075A1 (en) * | 2012-09-10 | 2016-04-21 | Gaming Arts LLC | Systems and methods for playing a game of chance with a plurality of prizes |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1014916T4 (en) * | 1997-08-18 | 2011-09-26 | Neubourg Skin Care Gmbh & Co Kg | The foam skin protection cream |
AUPP583198A0 (en) * | 1998-09-11 | 1998-10-01 | Soltec Research Pty Ltd | Mousse composition |
US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US6627178B1 (en) * | 1999-07-30 | 2003-09-30 | Garret D. Cawthon | Methods, compositions and systems for the prevention and treatment of diaper rash |
FR2807321B1 (en) * | 2000-04-06 | 2002-08-30 | Seppic Sa | NEW ACTIVE INGREDIENT, COMPOSITION CONTAINING THE SAME, AND USE IN COSMETICS, DERMOCOSMETICS, DERMOPHARMACY OR PHARMACY OR ON WOVEN OR NONWOVEN MEDIA |
FR2817769B1 (en) * | 2000-12-08 | 2003-09-12 | Hospal Ind | APPARATUS FOR THE EXTRACORPOREAL TREATMENT OF BLOOD OR PLASMA COMPRISING A WET SEMI-PERMEABLE MEMBRANE AND METHODS OF MANUFACTURE |
DE10063341A1 (en) * | 2000-12-19 | 2002-06-20 | Beiersdorf Ag | Cosmetic or dermatological composition contains three-part emulsifier system, lipid phase and gas |
DE10063342A1 (en) * | 2000-12-19 | 2002-06-20 | Beiersdorf Ag | Cosmetic or dermatological composition contains three-part emulsifier system and gas |
DE10063340A1 (en) * | 2000-12-19 | 2002-08-29 | Beiersdorf Ag | Self-foaming or foam-like preparations |
JP2002265347A (en) * | 2001-03-13 | 2002-09-18 | Shiseido Co Ltd | Cosmetic promoting maturation of cornified envelope |
DE10113050A1 (en) * | 2001-03-15 | 2002-09-19 | Beiersdorf Ag | Self-foaming or foamed cosmetic or dermatological composition comprises a specified emulsifier system, a lipid phase, a gas and an organic hydrocolloid |
DE10113046A1 (en) * | 2001-03-15 | 2002-09-26 | Beiersdorf Ag | Self-foaming product for dermatological and cosmetic products comprises an emulsifier system, a lipid phase, gas, organic hydrocolloid and a solid body |
DE10134786A1 (en) * | 2001-07-17 | 2003-02-06 | Beiersdorf Ag | Foamable preparations |
DE10144061A1 (en) * | 2001-09-07 | 2003-04-17 | Beiersdorf Ag | Self-foaming or foam-like preparations with inorganic gel formers, organic hydrocolloids and particulate hydrophobic and / or hydrophobized and / or oil-absorbing solid substances |
DE10147820A1 (en) * | 2001-09-27 | 2003-04-10 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing waxes or lipids which are solid and / or semi-solid at room temperature |
DE10155956A1 (en) * | 2001-11-09 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations |
DE10155792A1 (en) * | 2001-11-14 | 2003-05-22 | Beiersdorf Ag | Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing siloxane elastomers |
US20030170282A1 (en) * | 2002-03-05 | 2003-09-11 | Walz David K. | Method of skin protection during hair treatment |
ATE426417T1 (en) * | 2002-06-12 | 2009-04-15 | Sca Hygiene Prod Ab | ABSORBENT ARTICLE CONTAINING A SKINCARE COMPOSITION |
US8053626B2 (en) | 2002-06-12 | 2011-11-08 | Sca Hygiene Products Ab | Absorbent article containing a skincare composition and method of making and using same |
DE10228229A1 (en) * | 2002-06-25 | 2004-03-18 | Beiersdorf Ag | Foamable preparations |
US7544674B2 (en) * | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
DE10250755B4 (en) * | 2002-10-31 | 2007-02-08 | Merz Pharma Gmbh & Co. Kgaa | A foamable composition based on an O / W emulsion comprising a combination of a silicone-based emulsifier and an anionic surfactant having improved skin action, their preparation and their use |
WO2004052317A1 (en) * | 2002-12-12 | 2004-06-24 | Neubourg Skin Care Gmbh & Co. Kg | Stable foam cream |
GB0307866D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
US20070140999A1 (en) * | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
WO2005009406A1 (en) * | 2003-07-18 | 2005-02-03 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
DE10347824B4 (en) * | 2003-10-10 | 2011-08-11 | Lach, Hans-Joachim, Dr., 79331 | Pharmaceutical or cosmetic composition for the treatment of the skin |
US20060099173A1 (en) * | 2003-10-24 | 2006-05-11 | Nancy Puglia | Topical skin care composition |
AU2003274610A1 (en) * | 2003-11-05 | 2005-05-26 | Medena Ag | Foamed skin cream |
DE10356164A1 (en) * | 2003-12-02 | 2005-08-04 | Beiersdorf Ag | Active ingredient combinations of licochalcone A or an extract of Radix Clycyrrhizae inflatae, containing licochalcone A, phenoxyethanol and, if desired, glycerol |
DE202004021449U1 (en) * | 2004-10-21 | 2008-02-28 | Neubourg Skin Care Gmbh & Co. Kg | Use of urea for the treatment of age spots |
US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
AU2006253913B2 (en) | 2005-06-01 | 2010-09-16 | Mayne Pharma Llc | Vitamin formulation |
PL2046121T3 (en) * | 2006-07-14 | 2013-01-31 | Stiefel Res Australia Pty Ltd | Fatty acid pharmaceutical foam |
US7801502B2 (en) * | 2006-12-18 | 2010-09-21 | Aai Corporation | Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems |
DE102008020797A1 (en) | 2008-04-22 | 2009-10-29 | Aquyo Cosmetics Gmbh | Skin cream useful for e.g. treatment and/or prophylaxis of dry skin and/or skin damage in diabetic foot, comprises saccharide e.g. mannobiose, polysaccharide e.g. dextran, multivalent alcohol e.g. glycerol, urea, polycation and carrier |
US20090317503A1 (en) * | 2008-06-20 | 2009-12-24 | Ocusoft, Inc. | Eyelid Preparation and Method of Use |
US8895080B2 (en) | 2008-06-20 | 2014-11-25 | Ocusoft, Inc. | Compositions and kits for ocular treatment |
CA2646932A1 (en) * | 2008-12-10 | 2010-06-10 | Lancelot Biotech Inc. | Method for the topical application of a medicinal preparation |
ES2364692T3 (en) * | 2008-12-23 | 2011-09-12 | Intendis Gmbh | ESSENTIALLY FREE FOAM COMPOSITION OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR HUMAN SKIN TREATMENT. |
PL2335675T3 (en) | 2009-12-10 | 2015-08-31 | Neubourg Skin Care Gmbh & Co Kg | Emulsifier-free, polymer stabilised foam formulas |
US8409628B2 (en) * | 2010-02-04 | 2013-04-02 | Penguin IP Holdings, Inc. | Methods and compositions for oxygenation of skin to treat skin disorders |
EP2371350B1 (en) | 2010-03-04 | 2013-04-24 | Neubourg Skin Care GmbH & Co. KG | Foam formulas for treating animal skin illnesses |
US8900601B2 (en) | 2010-03-31 | 2014-12-02 | Jennifer Bartels | Permeable mixtures, methods and compositions for the skin |
DE102011018924A1 (en) | 2011-04-28 | 2012-10-31 | Tunap Industrie Chemie Gmbh & Co. Produktions Kg | OW emulsion concentrate, process for its preparation and skin cosmetic containing it |
WO2013106647A1 (en) * | 2012-01-13 | 2013-07-18 | Dharma Biomedical, Llc | Supercritical guggul extracts and uses thereof |
US9717679B1 (en) | 2012-12-17 | 2017-08-01 | Touchless Designs LLC | Methods for the prevention and treatment of animal skin conditions |
US9539275B2 (en) * | 2014-01-27 | 2017-01-10 | Hong Kong Baptist University | Melanogenesis effect of saponins of gynostemma pentaphyllum |
US10258646B2 (en) * | 2014-10-28 | 2019-04-16 | Andrea Rosanoff | Cream transdermal magnesium supplement |
DE102015221565A1 (en) | 2015-11-04 | 2017-05-04 | Beiersdorf Ag | Cosmetic foam of an emulsion containing glyceryl stearate citrate |
DE102015221567A1 (en) | 2015-11-04 | 2017-05-04 | Beiersdorf Ag | Cosmetic foam from an emulsion containing betaine |
DE102015221568A1 (en) | 2015-11-04 | 2017-05-04 | Beiersdorf Ag | Cosmetic foam of an emulsion containing glycerol and alcohol |
DE102015221566A1 (en) | 2015-11-04 | 2017-05-04 | Beiersdorf Ag | Cosmetic foam of an emulsion containing sodium cetearyl sulfate and glyceryl monostearate |
EP3468530A4 (en) | 2016-06-10 | 2020-03-11 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
DE102016223502A1 (en) | 2016-11-28 | 2018-05-30 | Beiersdorf Ag | UV-filter-containing, cosmetic foam comprising an emulsion containing sodium cetearyl sulfate and glyceryl monostearate |
DE102016224029A1 (en) | 2016-12-02 | 2018-06-07 | Beiersdorf Ag | Foaming emulsion-based cleaning preparation-1 |
CN113069942A (en) * | 2021-04-07 | 2021-07-06 | 杨梦玲 | Mild amino acid soap-based facial cleanser and preparation method thereof |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2968628A (en) * | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3666863A (en) * | 1968-03-06 | 1972-05-30 | Medisan Ab | Skin-treating composition and vehicle for skin-treating agents |
US3970584A (en) * | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US4137302A (en) * | 1976-04-02 | 1979-01-30 | Lever Brothers Company | Cosmetic composition |
US4145411A (en) * | 1974-09-05 | 1979-03-20 | Colgate-Palmolive Company | Pressurized foaming shaving composition |
US4459285A (en) * | 1981-02-27 | 1984-07-10 | Societe Anonyme Dite: L'oreal | Cosmetic composition for the treatment of the hair and skin comprising a powder of flowers or flower tops and a cohesion agent |
US4661340A (en) * | 1983-06-06 | 1987-04-28 | Interkemia Vegyipari Gazdasagi Tarsasag | Quail egg based stabilized foam compositions for cosmetic purposes |
US5000938A (en) * | 1988-08-12 | 1991-03-19 | Innovatec S.A. | Protective aerated foam hand lotion and process for preparing the same |
US5086903A (en) * | 1991-04-08 | 1992-02-11 | Interrolll Holding Ag | Tandem brake roller system |
US5139781A (en) * | 1990-02-13 | 1992-08-18 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Topical composition comprising mono- and di-alkyl or alkenyl phosphates and alkylamidopropyl betaines of alkylamphoglycinates |
US5278263A (en) * | 1992-10-05 | 1994-01-11 | The Goodyear Tire & Rubber Company | Syndiotactic 1,2-polybutadiene synthesis in an aqueous medium utilizing N,N-dibutylformamide as a modifier |
US5334387A (en) * | 1993-02-23 | 1994-08-02 | Colgate-Palmolive Company | Topical composition comprising mono and dialkyl phosphates with a cosurfactant |
US5439682A (en) * | 1991-11-22 | 1995-08-08 | Richardson-Vicks Inc. | Combined personal cleansing and moisturizing compositions |
US5472686A (en) * | 1990-12-28 | 1995-12-05 | Nippon Unicar Company Limited | Cosmetic formulations |
US5500211A (en) * | 1994-09-22 | 1996-03-19 | The Gillette Company | Soap-free self-foaming shave gel composition |
US5525588A (en) * | 1994-09-14 | 1996-06-11 | Elzabeth Arden Co. | Cosmetic composition |
US5621012A (en) * | 1994-06-14 | 1997-04-15 | Beiersdorf Aktiengesellschaft | Active compound combinations having a content of glyceryl alkyl ethers and cosmetic and dermatological formulations comprising such active compound combinations |
US5674511A (en) * | 1994-12-06 | 1997-10-07 | The Procter & Gamble Company | Shelf stable skin cleansing liquid with gel forming polymer, lipid and crystalline ethylene glycol fatty acid ester |
US5788972A (en) * | 1994-10-24 | 1998-08-04 | L'oreal | Product for topical application containing a lipase and an active ingredient precursor |
US5882659A (en) * | 1995-12-01 | 1999-03-16 | L'oreal | Use of a polyholoside in a cleaning or make-up-removing composition and composition comprising same |
US5902590A (en) * | 1994-03-03 | 1999-05-11 | Henkel Kommanditgesellschaft Auf Aktien | Cosmetic and/or pharmaceutical formulations |
USH2013H1 (en) * | 1997-05-23 | 2002-02-05 | The Procter & Gamble Company | Skin care compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4551480A (en) * | 1983-06-21 | 1985-11-05 | Stiefel Laboratories, Inc. | Compositions for the treatment of psoriasis |
DE3330628C2 (en) | 1983-08-25 | 1985-11-07 | Schülke & Mayr GmbH, 2000 Norderstedt | Skin protection and care lotion |
US5002680A (en) * | 1985-03-01 | 1991-03-26 | The Procter & Gamble Company | Mild skin cleansing aerosol mousse with skin feel and moisturization benefits |
DE3670569D1 (en) * | 1985-03-01 | 1990-05-31 | Procter & Gamble | Mild cleaning foam. |
DE3628531A1 (en) | 1986-08-22 | 1988-02-25 | Merz & Co Gmbh & Co | FOAMABLE CREAMS |
US5277336A (en) * | 1990-12-31 | 1994-01-11 | L'oreal | Device for the pressurized dispensing of a product, especially a foaming product, and processes for filling a container for a device of this kind |
DE4238860A1 (en) * | 1992-11-19 | 1994-05-26 | Medicon Gmbh | Skin protection products for the protection of human skin |
US5616746A (en) * | 1993-04-15 | 1997-04-01 | L'oreal | Use in cosmetics of lipophilic derivatives of amino deoxyalditols, cosmetic compositions containing them, and novel alkyl carbamates |
ZA946016B (en) | 1993-08-30 | 1996-02-12 | Colgate Palmolice Company | An aerosol shaving cream formulation |
US5534265A (en) * | 1994-08-26 | 1996-07-09 | The Procter & Gamble Company | Thickened nonabrasive personal cleansing compositions |
US5540853A (en) * | 1994-10-20 | 1996-07-30 | The Procter & Gamble Company | Personal treatment compositions and/or cosmetic compositions containing enduring perfume |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
US6086903A (en) * | 1996-02-26 | 2000-07-11 | The Proctor & Gamble Company | Personal treatment compositions and/or cosmetic compositions containing enduring perfume |
DK1014916T4 (en) * | 1997-08-18 | 2011-09-26 | Neubourg Skin Care Gmbh & Co Kg | The foam skin protection cream |
-
1998
- 1998-08-18 DK DK98943893.2T patent/DK1014916T4/en active
- 1998-08-18 JP JP2000509390A patent/JP4057234B2/en not_active Expired - Fee Related
- 1998-08-18 EP EP98943893A patent/EP1014916B2/en not_active Expired - Lifetime
- 1998-08-18 CA CA002300054A patent/CA2300054C/en not_active Expired - Lifetime
- 1998-08-18 DE DE59802564T patent/DE59802564D1/en not_active Expired - Lifetime
- 1998-08-18 US US09/485,930 patent/US6423323B2/en not_active Expired - Lifetime
- 1998-08-18 AT AT98943893T patent/ATE210954T1/en active
- 1998-08-18 ES ES98943893T patent/ES2170522T5/en not_active Expired - Lifetime
- 1998-08-18 AU AU91624/98A patent/AU9162498A/en not_active Abandoned
- 1998-08-18 WO PCT/EP1998/005232 patent/WO1999008649A2/en active IP Right Grant
- 1998-08-18 PT PT98943893T patent/PT1014916E/en unknown
-
2002
- 2002-07-17 US US10/196,726 patent/US20030059394A1/en not_active Abandoned
-
2005
- 2005-07-14 US US11/180,913 patent/US20060018938A1/en not_active Abandoned
-
2007
- 2007-12-11 US US12/000,314 patent/US20080213193A1/en not_active Abandoned
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2968628A (en) * | 1958-10-17 | 1961-01-17 | Shulton Inc | Propellant composition |
US3666863A (en) * | 1968-03-06 | 1972-05-30 | Medisan Ab | Skin-treating composition and vehicle for skin-treating agents |
US3970584A (en) * | 1973-02-14 | 1976-07-20 | S. C. Johnson & Son, Inc. | Aerosol package containing a foam-forming emulsion and propellent system |
US4145411A (en) * | 1974-09-05 | 1979-03-20 | Colgate-Palmolive Company | Pressurized foaming shaving composition |
US4137302A (en) * | 1976-04-02 | 1979-01-30 | Lever Brothers Company | Cosmetic composition |
US4459285A (en) * | 1981-02-27 | 1984-07-10 | Societe Anonyme Dite: L'oreal | Cosmetic composition for the treatment of the hair and skin comprising a powder of flowers or flower tops and a cohesion agent |
US4569839A (en) * | 1981-02-27 | 1986-02-11 | L'oreal | Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent |
US4661340A (en) * | 1983-06-06 | 1987-04-28 | Interkemia Vegyipari Gazdasagi Tarsasag | Quail egg based stabilized foam compositions for cosmetic purposes |
US5000938A (en) * | 1988-08-12 | 1991-03-19 | Innovatec S.A. | Protective aerated foam hand lotion and process for preparing the same |
US5139781A (en) * | 1990-02-13 | 1992-08-18 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Topical composition comprising mono- and di-alkyl or alkenyl phosphates and alkylamidopropyl betaines of alkylamphoglycinates |
US5472686A (en) * | 1990-12-28 | 1995-12-05 | Nippon Unicar Company Limited | Cosmetic formulations |
US5086903A (en) * | 1991-04-08 | 1992-02-11 | Interrolll Holding Ag | Tandem brake roller system |
US5439682A (en) * | 1991-11-22 | 1995-08-08 | Richardson-Vicks Inc. | Combined personal cleansing and moisturizing compositions |
US5278263A (en) * | 1992-10-05 | 1994-01-11 | The Goodyear Tire & Rubber Company | Syndiotactic 1,2-polybutadiene synthesis in an aqueous medium utilizing N,N-dibutylformamide as a modifier |
US5334387A (en) * | 1993-02-23 | 1994-08-02 | Colgate-Palmolive Company | Topical composition comprising mono and dialkyl phosphates with a cosurfactant |
US5902590A (en) * | 1994-03-03 | 1999-05-11 | Henkel Kommanditgesellschaft Auf Aktien | Cosmetic and/or pharmaceutical formulations |
US5621012A (en) * | 1994-06-14 | 1997-04-15 | Beiersdorf Aktiengesellschaft | Active compound combinations having a content of glyceryl alkyl ethers and cosmetic and dermatological formulations comprising such active compound combinations |
US5525588A (en) * | 1994-09-14 | 1996-06-11 | Elzabeth Arden Co. | Cosmetic composition |
US5500211A (en) * | 1994-09-22 | 1996-03-19 | The Gillette Company | Soap-free self-foaming shave gel composition |
US5788972A (en) * | 1994-10-24 | 1998-08-04 | L'oreal | Product for topical application containing a lipase and an active ingredient precursor |
US5674511A (en) * | 1994-12-06 | 1997-10-07 | The Procter & Gamble Company | Shelf stable skin cleansing liquid with gel forming polymer, lipid and crystalline ethylene glycol fatty acid ester |
US5882659A (en) * | 1995-12-01 | 1999-03-16 | L'oreal | Use of a polyholoside in a cleaning or make-up-removing composition and composition comprising same |
USH2013H1 (en) * | 1997-05-23 | 2002-02-05 | The Procter & Gamble Company | Skin care compositions |
Cited By (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US20080138293A1 (en) * | 2002-10-24 | 2008-06-12 | Foamix Ltd | Cosmetic and pharmaceutical foam |
US20090180970A1 (en) * | 2002-10-25 | 2009-07-16 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US20050074414A1 (en) * | 2002-10-25 | 2005-04-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20050205086A1 (en) * | 2002-10-25 | 2005-09-22 | Foamix Ltd. | Retinoid immunomodulating kit and composition and uses thereof |
US20050232869A1 (en) * | 2002-10-25 | 2005-10-20 | Foamix Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20050244342A1 (en) * | 2002-10-25 | 2005-11-03 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
US20050271598A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Body cavity foams |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20060140984A1 (en) * | 2002-10-25 | 2006-06-29 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US20060233721A1 (en) * | 2002-10-25 | 2006-10-19 | Foamix Ltd. | Foam containing unique oil globules |
US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US20070020304A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US20070253911A1 (en) * | 2002-10-25 | 2007-11-01 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US20070292355A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
US20070292359A1 (en) * | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US20080044444A1 (en) * | 2002-10-25 | 2008-02-21 | Foamix Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US20080253973A1 (en) * | 2002-10-25 | 2008-10-16 | Foamix Ltd. | Sensation modifying topical composition foam |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US20080317679A1 (en) * | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20070020213A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US20100284938A1 (en) * | 2002-10-25 | 2010-11-11 | Foamix Ltd. | Penetrating pharmaceutical foam |
US20100040561A9 (en) * | 2002-10-25 | 2010-02-18 | Foamix Ltd. | Penetrating pharmaceutical foam |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US20060269485A1 (en) * | 2002-11-29 | 2006-11-30 | Foamix Ltd. | Antibiotic kit and composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
US20040265240A1 (en) * | 2003-04-28 | 2004-12-30 | Foamix Ltd. | Foamable iodine composition |
US20110002857A1 (en) * | 2003-08-04 | 2011-01-06 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US20050069566A1 (en) * | 2003-08-04 | 2005-03-31 | Foamix Ltd. | Foam carrier containing amphiphilic copolymeric gelling agent |
US20080299220A1 (en) * | 2003-08-04 | 2008-12-04 | Dov Tamarkin | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050031547A1 (en) * | 2003-08-04 | 2005-02-10 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20070280891A1 (en) * | 2003-08-04 | 2007-12-06 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20100266510A1 (en) * | 2003-08-04 | 2010-10-21 | Foamix Ltd. | Foamable Vehicle and Pharmaceutical Compositions Thereof |
US20050075407A1 (en) * | 2003-08-25 | 2005-04-07 | Foamix Ltd. | Foam incorporating eutetic mixture |
US20050186147A1 (en) * | 2004-02-04 | 2005-08-25 | Foamix Ltd. | Cosmetic and pharmaceutical foam with solid matter |
US20080267890A1 (en) * | 2005-01-20 | 2008-10-30 | Kayban Pty Ltd. | Anti-Microbial Agent |
US9078845B2 (en) * | 2005-01-20 | 2015-07-14 | Kayban Pty Ltd | Anti-microbial agent |
US20060275221A1 (en) * | 2005-05-09 | 2006-12-07 | Foamix Ltd. | Saccharide foamable compositions |
US7645803B2 (en) | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US20080152596A1 (en) * | 2005-07-19 | 2008-06-26 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
US20070098647A1 (en) * | 2005-09-28 | 2007-05-03 | Neubourg Skin Care Gmbh & Co. Kg | Skin care products |
US20090175799A1 (en) * | 2006-09-08 | 2009-07-09 | Dov Tamarkin | Colored or colorable topical composition foam |
US20080166303A1 (en) * | 2006-09-08 | 2008-07-10 | Dov Tamarkin | Colored or colorable foamable composition and foam |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20100221195A1 (en) * | 2006-11-14 | 2010-09-02 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20110097279A1 (en) * | 2006-11-14 | 2011-04-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US20080206155A1 (en) * | 2006-11-14 | 2008-08-28 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
US20080292560A1 (en) * | 2007-01-12 | 2008-11-27 | Dov Tamarkin | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US20090130029A1 (en) * | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US20100310476A1 (en) * | 2007-12-07 | 2010-12-09 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US20110212033A1 (en) * | 2007-12-07 | 2011-09-01 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US20160107075A1 (en) * | 2012-09-10 | 2016-04-21 | Gaming Arts LLC | Systems and methods for playing a game of chance with a plurality of prizes |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Also Published As
Publication number | Publication date |
---|---|
US20080213193A1 (en) | 2008-09-04 |
CA2300054A1 (en) | 1999-02-25 |
DE59802564D1 (en) | 2002-01-31 |
EP1014916A2 (en) | 2000-07-05 |
US6423323B2 (en) | 2002-07-23 |
WO1999008649A3 (en) | 1999-05-14 |
DK1014916T3 (en) | 2002-04-15 |
DK1014916T4 (en) | 2011-09-26 |
ES2170522T5 (en) | 2011-11-14 |
AU9162498A (en) | 1999-03-08 |
EP1014916B2 (en) | 2011-06-15 |
US20030059394A1 (en) | 2003-03-27 |
WO1999008649A2 (en) | 1999-02-25 |
JP4057234B2 (en) | 2008-03-05 |
JP2001515022A (en) | 2001-09-18 |
ATE210954T1 (en) | 2002-01-15 |
PT1014916E (en) | 2002-06-28 |
ES2170522T3 (en) | 2002-08-01 |
EP1014916B1 (en) | 2001-12-19 |
US20020001599A1 (en) | 2002-01-03 |
CA2300054C (en) | 2003-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6423323B2 (en) | Foam skin cream, uses of the foam skin protection cream and a process for its preparation | |
US6407044B2 (en) | Aerosol personal cleansing emulsion compositions which contain low vapor pressure propellants | |
AU738286B2 (en) | Skin care composition with improved skin hydration capability | |
EP0095615A2 (en) | Skin conditioning composition | |
KR101242371B1 (en) | Novel skin care formulation | |
WO1999038491A1 (en) | Moisturizing personal cleansing compositions with improved lipid deposition | |
TW200914056A (en) | Stable high internal phase emulsions and compositions comprising the same | |
EP1051151A1 (en) | Liquid personal cleansing emulsion compositions which contain a weighting oil | |
JP3425019B2 (en) | Oily foam cleansing cosmetic | |
JP2944757B2 (en) | Cleansing composition containing hydroxyalkanoate derivative | |
US5869061A (en) | Protective hand lotion of aloe vera gel and vitamin E gel | |
KR100740598B1 (en) | Oil-in-water type emulsion cosmetic composition | |
JP3515154B2 (en) | Emulsified cosmetic | |
US5000938A (en) | Protective aerated foam hand lotion and process for preparing the same | |
JP3488479B2 (en) | Bath composition | |
JPH0730310B2 (en) | Anhydrous foam agent | |
Epstein | Formulating Cosmetic Products | |
DE29824900U1 (en) | Foam skin cream | |
KR100294246B1 (en) | S / W type makeup cosmetic composition | |
DE29825242U1 (en) | A foaming skin cream - contains special additives which make it useful for treating allergies or preventing skin from absorbing carcinogens | |
AU2009202123A1 (en) | Aerosol Moisturiser | |
KR101074516B1 (en) | Bodied cream cosmetics composition | |
CN111088118A (en) | Cleaning composition | |
JPH0818970B2 (en) | Bath agent composition | |
JP2006321915A (en) | Foam aerosol composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUBOURG, STEPHANIE;REEL/FRAME:019161/0303 Effective date: 20070320 |
|
AS | Assignment |
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY Free format text: CORRECTIV;ASSIGNOR:NEUBOURG, STEPHANIE;REEL/FRAME:019254/0492 Effective date: 20070320 Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY Free format text: CORRECTIVE ASSIGNMENT TO CHANGE "ISSUED PATENT NUMBER" UNDER SECTION 4 FROM "6423434" TO -6423323--(PREVIOUSLY RECORDED AT R/F 019161/0303);ASSIGNOR:NEUBOURG, STEPHANIE;REEL/FRAME:019254/0492 Effective date: 20070320 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |